Atogepant for episodic migraine: brain and body effects
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests a daily pill called atogepant to see how it affects the brain and body in people with episodic migraine. It may help if you have 8 to 14 migraine days a month and haven't tried CGRP treatments before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with episodic migraine (not chronic daily migraine).
- You have 8 to 14 migraine days each month (high-frequency pattern).
- You have never taken a CGRP-targeted treatment (like Aimovig, Emgality, or Ajovy).
- You take no more than one migraine preventive medication, and the dose has been stable for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at the chemical changes in the blood of people with migraine. It aims to better understand the disease and may help find new treatments. You may qualify if you have episodic or chronic migraine and have not tried CGRP-targeting drugs.
This study tests whether an oral medicine called atogepant can reduce migraine activity in children ages 6–17 and checks its side effects. It’s meant for kids with episodic migraine (not the more constant types) who may benefit from preventive treatment.
This study tests a once-daily pill, atogepant, to see if it safely prevents chronic or episodic migraines in Korean adults. It's meant for people whose doctor has already prescribed the pill for migraine prevention.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
This study is building a database to learn more about migraine drugs. It may help researchers find better treatments for people with episodic or chronic migraine.
This study tests a CGRP-blocking antibody to see how it affects migraine symptoms and the body’s automatic (involuntary) nerve functions. It may help people with migraine who have already tried several preventive medicines.
Hear when a new Episodic Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.